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Obesity has become a global epidemic with a soaring economic encumbrance due
to its related morbidity and mortality. Amongst obesity-related conditions, cancer is
indeed the most redoubtable. Bariatric surgery has been proven to be the most
effective treatment for obesity and its associated metabolic and cardiovascular disorders.
However, the understanding of whether and how bariatric surgery determines a
reduction in cancer risk is limited. Obesity-related malignancies primarily include
colorectal and hormone-sensitive (endometrium, breast, prostate) cancers. Additionally,
esophago-gastric tumors are growing to be recognized as a new category mainly
associated with post-bariatric surgery outcomes. In fact, certain types of surgical
procedures have been described to induce the development and subsequent
progression of pre-cancerous esophageal and gastric lesions. This emerging category is
of great concern and further research is required to possibly prevent such risks. Published
data has generated conflicting results. In fact, while overall cancer risk reduction was
reported particularly in women, some authors showed no improvement or even increased
cancer incidence. Although various studies have reported beneficial effects of surgery
on risk of specific cancer development, fundamental insights into the pathogenesis of
obesity-related cancer are indispensable to fully elucidate its mechanisms.
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INTRODUCTION
The incessant rise of obesity and overweight have configured a state of global epidemic, affecting 1.9
billion and 650 million adults worldwide by 2016, respectively (1). Overall mortality is increased by
obesity and its related conditions (2). Amongst these, cancer is indeed the most redoubtable. High
body mass index (BMI), namely BMI > 40 kg/m2, has clearly been linked to a greater risk of both
common a rare malignancy incidence and mortality rates (3, 4).
Obesity-related neoplasms primarily include colorectal and hormone-sensitive (endometrium,
postmenopausal breast, prostate) cancers. Bariatric/metabolic surgery (BMS) has been extensively
acknowledged to be the most efficacious treatment option for the cure of severe obesity and
the number of procedures performed is exponentially growing globally (5–7) (Figure 1). Overall
mortality has also been demonstrated to be decreased after BMS (8). On the contrary, it is uncertain
whether BMS has any influence over cancer-related mortality.
It is certainly the remission of obesity that has been postulated to be at the basis of cancer
incidence reduction or prevention (3, 9–11). Mechanisms involved in obesity-related cancer
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genesis are multiple and not completely elucidated. Some of these
have been suggested to occur through a depauperation of adipose
tissue, which causes in parallel a drop in estrogen circulating
levels, thereby altering the risk of hormone-sensitive cancers,
especially in postmenopausal women (12, 13). Insulin resistance,
which is known to often co-exist with obesity, might also have
a role in augmented estrogen levels through interaction in
insulin signaling pathways, possibly causing exogenous estrogen
synthesis (14). Furthermore, several weight loss independent
modalities have been proposed to be involved in post-bariatric
surgery cancer risk decrease (15) and include lowering of
systemic inflammation and inflammatory markers, changes in
gastrointestinal hormones, alteration of gastrointestinal anatomy
which in turn produces alteration of gut microbiota, fat, glucose
and bile metabolism (16).
Available data has generated differing results; while overall
cancer risk reduction was reported particularly in women,
some authors showed no improvement or even increased
cancer incidence.
Herein, we analyze the link between obesity and cancer,
reported influence of BMS on outcomes in terms of obesity-
associated cancer incidence and mortality and possible
mechanisms involved in its genesis.
OBESITY AND OVERALL CANCER RISK
There is a well-established association between the risk of
developing several types of cancers and the presence of an
increased BMI (i.e., ≥ 25 kg/m2) (3). With an ever-growing
obesity and overweight prevalence worldwide, it would be
sensible to also expect a concomitant rise in cancer incidence.
Approximately 481,000 or 3.6% of all newly diagnosed cancers
worldwide in adults aged 30 years or more were considered to be
presumably caused by an increased BMI, in 2012. In turn, 13% of
all cancers correlated to obesity could be attributable to a raised
BMI in the adult population (17, 18). A projected rise of cancer
risk development ranging 3-10% was associated to every unit
increase in BMI (3). Another projection by the Global Burden of
Disease group estimated a 3.9% of all cancer deaths to be linked
to excess BMI (19). However, it is likely that these reckonings
might be inaccurate due to several possible confounding factors
or modifiers such as additional effects of smoking or replacement
hormonal therapy. Additionally, most computations do not take
into account the latency time, of ∼10 years, which elapses
between the rise in BMI and the development of a malignancy.
Abbreviations: BMI, Body Mass Index; BMS, Bariatric/Metabolic Surgery; NK,
Natural Killer; Treg, Regulatory T Cells; IGF-1, Insulin-Like Growth Factor
1; VAT, Visceral Adipose Tissue; SAT, Subcutaneous Adipose Tissue; HIF-1-α,
Hypoxia-Inducible Factor 1 Alpha; COX-2, Cycloxygenase 2; PGE2, Prostaglandin
E2; SHBG, Sex-Hormone Binding Globulin; NAFLD, Non-Alcoholic Fatty Liver
Disease; NASH, Non-Alcoholic Steatohepatitis; HCC, Hepatocellular Carcinoma;
SOS, Swedish Obese Subjects; SIR, Standardized Incidence Ratio; GERD,
Gastroesophageal Reflux Disease; VBG, Vertical Banded Gastroplasty; AGB,
Adjustable Gastric Banding; SG, Sleeve Gastrectomy; RYGB, Roux-en-Y Gastric
Bypass; OAGB, One Anastomosis Gastric Bypass; IFSO, International Federation
for the Surgery of Obesity and Metabolic Disorders.
A recent population-based registry study analyzing the
incidence of cancer in Nigeria amongst subjects affected by
obesity and overweight, found an estimated 1.4%, similarly to
other developing countries. Interestingly, when comparing such
incidence with other developed countries such as United States,
United Kingdom and Australia, this was substantially lower. In
fact, the incident cancers attributable to obesity and overweight
were 6.0% in the United States, 5.5% in United Kingdom, and
3.4% in Australia, due to a higher prevalence of overweight
and obesity in the aforementioned countries (20). Distinctively,
North America showed the greatest obesity-related cancer
incidence with an∼23% or 111,000 cases, while the Sub-Saharan
Africa had the lowest rates of 1.5% or 7,300 cases (17). Hence, it
is evident how obesity and overweight rates go hand in hand with
cancer risk and that profound variations exist in its incidence
according to the countries’ level of development.
Excess BMI significantly influences cancer risk according
to difference in gender. In fact, while it was estimated to
affect 1.9% or 136,000 males in 2012, the risk was more than
doubled in females (i.e., 5.4% or 345,000 cases). Furthermore,
cancer sites vary greatly amongst genders. Breast (33.1% of all
obesity/overweight-related cancers) and uterus (31.1%) were the
most represented malignancies in females followed by colorectal
(10.4%), gallbladder (9.3%), renal (8.7%), pancreatic (3.4%), and
esophageal (1.2%) cancer. On the other hand, the most common
obesity/overweight-related cancer in males were colorectal
neoplasms (54%) accompanied by renal (24.8%), pancreatic
(10.9%), and esophageal (10.2%) cancer (17, 18). Thus, excess
BMI-related cancer risk was found to be substantially greater in
women compared to men, regardless of the geographical location
(Figure 2).
OBESITY-RELATED CANCER AND
SYSTEMIC INFLAMMATION
Obesity is characterized by a state of low-grade systemic
inflammation. This chronic generalized inflammatory condition
contributes to the development of metabolic morbidities
distinctive of obesity, in addition to possibly mediating cancer
genesis (21). Chronic inflammation has been demonstrated
to be at the basis of tumor promotion and growth. In fact,
inflammatory cells and its mediators have been shown to be
present in tumoral tissue and are able to induce cell proliferation
and migration, also contributing to neoangiogenesis (22).
Obesity per se is not directly considered to be a cancer
risk predictor. In contrast, it is indeed the coexistence of a
chronic low-grade systemic inflammation, which is thought to be
fundamental in promoting cancer. Confirming this observation,
is the fact that “metabolically healthy” obese subjects are
characteristically not affected by metabolic dysfunction which
is in turn caused by chronic inflammation. In “metabolically
unhealthy” obese individuals, instead, an inflammatory status is
responsible for the onset of metabolic dysregulation, increased
cardiovascular risk and obesity-related cancers (21).
Adipose tissue is growing to be considered as the vastest
endocrine organ of the human body, secreting numerous
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FIGURE 1 | Bariatric/metabolic operations performed worldwide by region between 2014 and 2018 This figure is original and based on data from Welbourn et al. [7].
cytokines, adypokines and chemokines. Imbalance between
caloric intake and expenditure leads to excessive fat deposition
and adipose depot expansion. This adipose depot overgrowth
causes tissue dysfunction and alteration of its histology due
to increased apoptosis, macrophage recruitment and release
of several pro-inflammatory molecules, typical of adipose
inflammation. Consequently, this contributes to peripheral
insulin resistance, hyperglycemia, dyslipidemia, all of which are
involved in inducing oxidative stress, cancer development and
sustainment (23).
It is important to note how not all types of inflammatory
processes are linked to cancer. In actual fact, a distinctive
feature of acute inflammation is the presence of natural killer
(NK) and CD8+ T cells at the interested site, also involved
in tumor immunity. On the contrary, chronic inflammatory
sites are lacking these types of cell populations (24). This tissue
is instead characterized by a reduction of anti-inflammatory
TH2 and regulatory T cells (Treg) with an increase in the
population of TH1 and CD8+ T cells, in addition to a shift of
the M2:M1 macrophage ratio (25). It is this very same type of
chronic inflammation of the adipose tissue, which is involved in
metabolic dysfunction, cardiovascular risk and carcinogenesis.
A balance between anti-inflammatory and pro-inflammatory
factors and immune system cells is present in healthy lean
adipose tissue and is capable of maintaining its normal storage
capacity, endocrine and whole-body metabolic function.
Alteration of this fine equilibrium is responsible of adipocyte
hypertrophy, mitochondrial dysregulation, endoplasmic
reticulum and oxidative stress, ultimately leading to the release
of pro-inflammatory factors and finally cellular apoptosis. This
configures a state of adipose inflammation. Adipose tissue
ability to store energy and to perform its normal endocrine
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FIGURE 2 | Cancer risk worldwide attributable to overweight and obesity, according to gender. (A) Females; (B) Males. Data are expressed in %. This figure is original
and based on data from Arnold et al. [16].
functions is deeply hampered in obese subjects. In regular
conditions, stromal cells are responsible of suppressing tumor
growth. Adipose inflammation and the altered adipokine and
cytokine secretion can modify this microenvironment and also
promote tumor growth, progression and tumor cell migration.
Additionally, this inflammatory state causes insulin resistance
which translates into a state of hyperglycemia, hyperinsulinemia,
increased circulating insulin-like growth factor 1 (IGF-1) which
have also been recognized to be involved in carcinogenesis (25)
(Figure 3).
Local inflammation seems to also play a substantial role
especially in breast cancer development. White adipose tissue
inflammation in the breast causes histological alterations and
release of NFκB, which leads to augmented aromatase activity
and estrogen-androgen ratio in the breast tissue. Local and
systemic raised estrogen levels are ideal for tumor formation and
progression (21).
Epigenetic variations in DNA over time have also been
proposed among chief determinants linking obesity and cancer.
Several environmental factors, including nutrition, physical
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FIGURE 3 | Mechanisms linking obesity to carcinogenesis. IGF-1, Insulin-Like Growth Factor 1; HIF-1-α, Hypoxia-Inducible Factor 1 Alpha; PI3K, Phosphoinositide
3-kinase; ERK, extracellular signal-regulated kinase; COX-2, Cycloxygenase 2; PGE2, Prostaglandin E2; SHBG, Sex-Hormone Binding Globulin. (The figure was
created using Servier Medical Art).
exercise and lifestyle, may be involved in such mechanisms,
via the activation of inflammatory processes (26). Recent
investigations in animal models have shown how diet-induced
obesity can decrease DNA methylation and downregulate
expression of certain genes, promoting breast cancer with a
worsened prognosis. Preventivemeasures and strategies targeting
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epigenetic changes are starting to be developed in order to disrupt
this linkage (27).
OBESITY-RELATED CANCER AND INSULIN
RESISTANCE
Central obesity measured by waist circumference has been found
to be a direct predictor of cancer risk. In other words, it is visceral
fat rather than peripheral adipose tissue which is correlated with
this very risk (28, 29). To this regard, visceral adipose tissue
(VAT) has increased lipolytic and lipogenic action additionally
to its greater pro-inflammatory factors secretion, compared
to subcutaneous adipose tissue (SAT). Metabolic dysfunction
and cardiovascular risk are both associated with greater VAT
depots (29).
Excess body weight contributes to inducing a state of insulin
resistance, characterized by augmented hepatic gluconeogenesis,
reduced peripheral glucose uptake and hyperinsulinemia.
Prolonged hyperinsulinemia may lead to increased IGF-
1 secretion (30). In vitro studies have demonstrated the
fundamental role of IGF-1 and insulin itself in stimulating
tumoral cell growth. Similarly, epidemiological investigations
have shown a direct correlation between increased insulin and
IGF-1 circulating levels and the development of certain types
of malignancies (i.e., pancreatic, liver, colorectal, breast, and
endometrium). Furthermore, IGF-1 is capable of promoting
tumoral development and sustainment, also stimulating hypoxia-
inducible factor 1 alpha (HIF-1-α) release that is associated with
specific tumor migration and metastasis and may inhibit certain
tumor suppressor genes such as p53. Insulin, on the other hand,
also has a role in tumor progression and metastasis through
stimulation of different intracellular pathways comprising PI3K
and ERK (31, 32) (Figure 3).
Mounting evidence has additionally shown that cancer
prognosis is affected by insulin and IGF-1 circulating
levels, independently of cancer risk. Specifically, a state of
hyperinsulinemia is associated with worst cancer prognosis
and outcomes. In consideration of the ever-growing obesity
global epidemic, insulin resistance and hyperinsulinemia, closely
interrelated with obesity, are receiving increasing attention and
new experimental antineoplastic drugs—targeting IGF-1 and/or
insulin signaling pathways—are being employed in clinical
trials (31).
OBESITY-RELATED CANCER AND
CIRCULATING ESTROGEN LEVELS
There is a rise in estrone, free and bound estradiol levels in
parallel to a rise in BMI (33). The main source of aromatase
in the human body resides in preadipocytes, adipocytes, and
mesenchymal stem cells found in the adipose tissue. This enzyme
is responsible for transforming androgens to estrogens. Levels
and function of aromatase increase proportionally to adiposity
and aging, with adipose tissue becoming the main secretion
site in postmenopausal women. Furthermore, chronic adipose
inflammation produces an increased cycloxygenase-2 (COX-
2) expression and prostaglandin E2 (PGE2) secretion which
combines with the already high levels of local pro-inflammatory
cytokines; this scenario is capable of inducing aromatase
expression and augmented estrogen production, configuring an
optimal microenvironment for carcinogenesis. Eicosanoids have
also shown to generate tumor cell migration, neoangiogenisis
and cell growth, due to its anti-apoptotic and pro-mitotic
pathways (34).
Sex-hormone binding globulin (SHBG) levels are also
profoundly affected by the amount of adipose tissue as
they decrease when adiposity rises. A reduction in SHBG
concentration causes a greater portion of estrogen to be bioactive
and readily available (35).
Hence, obesity is responsible of increasing estradiol
production in adipose tissue and elevating the fraction of
biologically active estrogen by influencing SHBG synthesis by the
liver (34). The augmented concentration of total serum estrogens
and low SHGB levels have been demonstrated to have a causal
relationship with postmenopausal breast and endometrial cancer
risk development (Figure 3).
OBESITY-RELATED CANCER AND GUT
MICROBIOTA
Over the past decade, a large body of literature has been
dedicated to investigating the role of gut microbiota in the
physiopathological mechanisms involved in metabolic regulation
in the ambit of cardio-metabolic disorders. Gut microbiota is
mostly present in the ileum and colon and is involved in the
host defensive action from pathogens, growth and development
of the digestive tract, immune response, balance of energy
homeostasis, and digestion of nutrients. Its composition is greatly
influenced by genetic background, diet, exercise and antibiotics.
Obesity and type 2 diabetes mellitus in humans have been
linked to alteration in gut microbiota composition. In turn,
through energy harvesting of dietary nutrients, gut microbiota
can indirectly affect insulin signaling and systemic low-grade
inflammation (36). A direct relationship between gut microbiota
and gastrointestinal cancers has been shown to occur by way
of systemic inflammation and immune response regulation.
The gut barrier dysfunction was proven to activate several
different pathways, able to promote the development of certain
gastrointestinal cancers, including colorectal, hepatocellular and
pancreatic cancers (37). BMS induces changes in gut microbiota,
which is involved in weight loss, fat deposition normalization,
indirectly contributing to cancer risk reduction (36).
OBESITY-RELATED CANCER AND
NON-ALCOHOLIC FATTY LIVER DISEASE
Non-alcoholic fatty liver disease (NAFLD) includes a clinical
continuum of hepatopathies that range from simple steatosis to
non-alcoholic steatohepatitis (NASH) and possibly evolving to
liver fibrosis, cirrhosis and hepatocellular carcinoma (HCC). As
a result of the ever-rising incidence of overweight, obesity and
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type 2 diabetes mellitus worldwide, NAFLD has become the most
commonly diagnosed liver condition in industrialized countries.
Approximately 25% of subjects with NASH develop progressive
fibrosis and subsequent cirrhosis (38). Several authors have
demonstrated how NAFLD has presently become the main risk
factor for the development of HCC, compared to previously
recognized predisposing causes such as hepatitis B and C
infection (39).
BMS is recommended in those patients affected by morbid
obesity in which pharmacotherapy and lifestyle modifications
have failed. However, no randomized controlled trials (RCTs)
comparing BMS with standard of care have been published until
now. A prospective study including 109 subjects demonstrated
histological resolution of NASH 1 year after RYGB, bilio-
intestinal bypass or gastric banding in 85% of the cases (40).
The same authors (41) showed in 381 subjects undergoing liver
biopsy during BMS, mainly RYGB, that the percentage of subjects
with NASH declined from 27.4 to 14.2% at 5 years, even though,
fibrosis somewhat worsened.
A recent meta-analysis (42) including 3093 liver biopsies
demonstrated resolution of steatosis in 66%, inflammation in
50%, ballooning in 76%, and fibrosis in 40% of the cases.
However, in 12% of subjects fibrosis worsened if present at the
baseline or appeared if absent.
The reduction of NAFLD or NASH prevalence in subjects
operated of BMS should translate in a future reduction in the
incidence of HCC.
EFFECTS OF BARIATRIC/METABOLIC
SURGERY ON OBESITY-RELATED
CANCER
Bariatric/metabolic surgery seems to have protective effects with
regards to cancer development and prognosis. However, this
anticarcinogenic action has been shown to be multifactorial and
may include weight-dependent and independent mechanisms.
Interestingly, several studies have shown a lack of correlation
between the entity of weight loss after BMS and the decrease
in cancer incidence (15, 43). This is to further confirm how
BMS exercises its effects not solely through excess weight loss,
but is rather likely to be mediated by various mechanisms.
These might include substantial reduction in pro-inflammatory
molecule secretion, alteration of gut microbiota, changes in
glucose and fat metabolism, improvement of insulin sensitivity,
modification of gastrointestinal peptides (15, 21, 24, 31, 32).
Some authors found beneficial effects of BMS in terms
of reduction of cancer incidence and mortality in females,
especially in the postmenopausal subgroup; the same benefit
was not proven in males (43, 44). Such positive outcomes in
females are likely to be associated with a substantial decrease
in estrogen production and bioavailability, translating in a
decline of hormone-sensitive breast and endometrial cancers
after BMS (15).
A 2-cohort observational study by Christou et al. comparing
patients who received BMS to a control group who did
not undergo surgery, demonstrated in parallel with an excess
weight loss of 67.1%, a 76% overall reduction of hospital
visits for all types of cancers in the post-bariatric group
(2.0 and 8.45%, respectively). Moreover, relative risk of breast
cancer incidence in the study group had an additional 82%
reduction (45). Similarly, Adams et al. conducted a retrospective
analysis assessing the effects of BMS (specifically, gastric bypass)
compared to non-surgical obese patients, on cancer incidence
and mortality over a 24-year period. Significantly lower cancer
frequency was found in the surgical group compared to non-
operated controls, with cancer-specific mortality decreased
by 46% in the former group. Although cancer incidence
declined only for obesity-related malignancies (i.e., esophagus,
colorectal, pancreas, postmenopausal breast, uterus, kidney, liver,
gallbladder), mortality dropped for all cancer types (45, 46).
McCawley et al. further investigated the influence of BMS
in female obese subjects in a retrospective study compared to
a non-surgical control group. Both groups were found to be
younger in age at diagnosis in comparison to the general non-
obese population. Furthermore, the non-operated control group
had a higher incidence of cancer rates compared to operated
subjects (5.8 vs. 3.6%, respectively). Most commonly diagnosed
malignancies in both groups were breast, endometrial, cervix and
colorectal cancers (47).
The Swedish Obese Subjects (SOS) study was the first
prospective controlled intervention trial to evaluate the impact
of BMS on cancer rates and outcomes after a mean 10.9-
year follow up period. Authors concluded that surgical patients
had substantially lower cancer prevalence, however, this was
confirmed in women but not the same was found in operated
men (43).
A systematic review and meta-analysis involving six
observational studies comparing outcomes in terms of cancer
risk and mortality in surgical vs. non-surgical obese subjects
concluded that BMS is capable of reducing overall cancer
incidence and related mortality. Nevertheless, after stratifying
patients by gender, beneficial effects of surgery were seen in
women but not confirmed in post-bariatric surgical men (48).
To further investigate the observation that substantial weight
loss might prevent the risk of developing endometrial hyperplasia
and type 1 endometrial cancer, Argenta et al. performed
a prospective, blinded, non-interventional pilot study on 45
premenopausal morbidly obese women candidate to BMS.
Authors found endometrial pathology (simple or complex
endometrial hyperplasia) in 6.8% of the study group at baseline
and observed a complete regression of the endometrial lesions
in all patients 12–18 months postoperatively. In this group of
patients a significant risk reduction of endometrial malignancies
was recorded but not abolished (49). Clinical trials are currently
underway to establish whether bariatric surgery coupled with
hormonal therapy is an effective treatment for endometrial
cancer/atypical hyperplasia in obese women of childbearing
age who wish to maintain their fertility and might help to
unravel possible molecular mechanisms causing endometrial
cancer reduction after BMS.
A Swedish nationwide population-based cohort study on
13,123 subjects, by Ostlund et al. analyzed the effect of BMS
on long-term obesity-related cancer (breast, prostate, colorectal,
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endometrial, and kidney) risk and mortality over a 26-year
period, calculated by a standardized incidence ratio (SIR). In
contrast to the aforementioned studies, Ostlund et al. failed to
show a protective effect of surgery on oncologic outcomes in the
long term after BMS. Specifically, authors found no reduction of
SIRs after BMS over time for all obesity-related cancers, except
for colorectal cancer, which had an increased SIR in the long-term
for post-bariatric subjects (50).
Colorectal cancer has been shown to be closely associated
with obesity, increasing alongside the rise in BMI. It has been
suggested that for every increase of 5 kg/m2 in BMI, colorectal
cancer risk increases by 24% in males and 9% in females
(3). A recent systematic review and meta-analysis by Afshar
et al., analyzing the effects of BMS solely on colorectal cancer
incidence, demonstrated a significantly diminished risk, by an
estimated 27% in obese operated patients compared to controls
(49, 51). However, data in literature regarding this specific risk
is inconsistent. Several authors have highlighted the protective
effects of BMS on overall cancer risk (3, 36, 45). However,
the majority of studies did not demonstrate adequate statistical
power nor sufficient length of follow up, which is needed
especially for colorectal malignancies, which do have indeed a
long decennary carcinogenetic process.
Similarly to findings by Ostlund et al. (50), Derogar et al.
(52) highlighted the rise in SIRs for colorectal cancer in the
post-bariatric surgical group composed of 15,095 patients, which
increased concurrently with time after surgery, compared to the
non-operated group (62,016 subjects) who’s SIRs continued to
be stable also in the long term. Interestingly, authors did not
find any difference in SIRs for colorectal cancer in-between the
different surgical procedures analyzed in the study (i.e., VBG,
AGB, and RYGB). The grounds for such increase is unclear,
but the same authors also demonstrated in a previous study
how patients who underwent RYGB developed rectal mucosal
hyperproliferation persisting at least 3 years postoperatively.
Furthermore, a raisedmucosal expression of the pro-tumorigenic
cytokine macrophage migration inhibitory factor was found (53).
It has been hypothesized that colorectal cancer development
might increase as a consequence of the malabsorptive effects
caused by certain bariatric procedures, where RYGB is the most
studied one. The altered intestinal absorption and the surgical
bowel rearrangement might lead to the increased mucosal bile
salt exposure and modification of gut microbiota. Additionally,
the modified dietary intake after surgery, principally composed
of proteins and low in carbohydrates, can contribute to the
production of harmful metabolites in the colonic tract with
possible cytotoxic effects on the mucosa and playing a role in the
complex interaction with gut microbiota and bile salts (54, 55).
Existing evidence derives largely from observational
retrospective studies, which might represent a selection bias and
may influence the reliability of results. Nevertheless, the vast
majority of studies available in literature undeniably highlight the
positive impact of BMS on specific cancer incidence, prognosis
and mortality. This may occur through several pathways that are
correlated to weight loss but also involve multiple mechanisms
that go beyond mere weight reduction and that seem to be also
associated to metabolic modifications that occur after surgery.
BARIATRIC/METABOLIC SURGERY AND
NEW ONSET OF GASTROESOPHAGEAL
CANCER
Overweight and obesity have been linked to a raised risk of
esophageal and gastric cancer development and this has been
shown to increase along with rising BMI (56). This correlation
(particularly present for malignancies of the distal esophagus
and cardia) has been attributed to the higher coexistence in
this population of gastroesophageal reflux disease (GERD), hiatal
hernia and subsequent erosive esophagitis of variable degrees
which may seldom evolve to Barrett’s esophagus (57, 58).
Helicobacter pylori infection concurrently plays a role in cancer
development, especially for gastric malignancies and is in fact
classified as a type 1 carcinogen (59). Additionally, hormonal
effects generated by dysregulation of insulin and IGF-1 secretion,
generally altered in obese subjects, may be implicated in this
carcinogenic process (30, 31).
By surgically inducing weight loss, BMS could presumably
reduce some risk factors implicated in gastroesophageal
tumorigenesis. However, scarce and contrasting evidence has
been reported in literature to this regard.
Bariatric procedures encompassing a restriction of the gastric
outlet, such as vertical banded gastroplasty (VBG), adjustable
gastric banding (AGB), and sleeve gastrectomy (SG), are
characterized by certain pathophysiologic modifications possibly
involved in gastroesophageal malignancy development. These
might comprise alimentary bolus stasis and impaction in
the esophagus or gastric pouch due to the presence of a
narrowed outlet, local inflammation adjacent to the gastric band
location, alteration of gastroesophageal intraluminal pressures
and motility with consequent appearance of differing types of
gastroesophageal reflux.
The protracted stasis of food content in the distal esophagus
or gastric reservoir might expose the mucosa to the harmful
effects of exogenous carcinogens (60, 61). Furthermore, certain
studies have investigated the local alterations arising in
correspondence to the gastric band or mesh (i.e., VBG,
ABG). The presence of a foreign body in fact, causes the
formation of adhesions, scar retraction, erosion, ulceration,
local blood flow reduction and mucosal changes leading to
metaplasia that in rare cases may evolve to dysplasia and
adenocarcinoma (62–64).
The role of chronic GERD has been proven to have
a fundamental role in the genesis of gastroesophageal
malignancies. Due to this, extensive research has been dedicated
to further understand the effects of BMS on GERD. Specifically,
SG was the bariatric procedure which raised the greatest
concerns in consideration of its exponentially rising popularity.
The effects of SG on GERD are rather conflicting (65). However,
several studies have demonstrated that SG substantially causes
de novo or a worsening of preexisting GERD, development of
erosive esophagitis and hiatal hernia as evaluated by the use
of endoscopy (66, 67). Interestingly, no correlation was found
between the presence of GERD symptoms and endoscopic
findings; indeed authors demonstrated how the vast majority
of patients often were asymptomatic for pyrosis, reflux or
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regurgitation (68). Furthermore, a peculiarity of SG is that the
composition of refluxate undergoes profound modifications
after surgery and is characterized by the greater presence of bile
(66, 67). Our previously published data on endoscopy before
and after SG actually confirmed the consensual increase of bile
stagnation into the esophagus, which strongly correlated with
the degree of erosive esophagitis and Barrett’s metaplasia (66).
Earlier investigations suggest that biliary or mixed types of
gastroesophageal reflux are responsible for esophageal mucosal
injury contributing to the development of Barrett’s esophagus
(69). Several studies actually reported a significantly elevated
number of Barrett’s esophagus after SG (66, 67, 70), reaching a
prevalence as high as 18.8% 5 years after this bariatric operation
(70). Barrett’s esophagus is considered to be a precancerous
lesion and some authors have suggested that this histological
alteration might evolve to dysplasia even more rapidly after SG
(66, 69). Esophageal adenocarcinoma is in fact the most common
malignancy emerging after SG and this might occur on previous
metaplasia. However, to this regard, reported cases in literature
are sporadic and do not allow to make definitive conclusions on
the actual prevalence of such malignancies (70).
After bypass surgery, namely, Roux-en-Y gastric bypass
(RYGB), the second most commonly performed bariatric
operation, several authors have described tumors arising mainly
from the gastric remnant. The excluded stomach might be a
site of carcinogenesis due to the accumulation of pancreatic and
biliary content at this level that has been shown to generate
in experimental studies the progression to intestinal metaplasia
and adenocarcinoma (71). Helicobacter Pylori infection has been
clearly linked to gastric cancer and some studies have shown
how this infection may persist in the gastric remnant after RYGB
despite eradication (72). This further supports the importance of
its treatment and eradication prior to RYGB (73).
One anastomosis gastric bypass (OAGB) has gained
popularity over the past five years and was recently accepted as
a standard bariatric procedure by the International Federation
for the Surgery of Obesity and Metabolic Disorders (IFSO).
This procedure has been hypothesized to potentially cause
the development of gastric cancer, owing to its peculiar
bypass reconstruction. Previous studies have clearly shown the
appearance of gastric adenocarcinoma at the level of the gastro-
jejunostomy after Billroth II reconstruction (74, 75). Considering
the fact that in OAGB a similar loop reconstruction is performed,
it could presumably be linked to a similar carcinogenetic risk to
that seen after Billroth II (76). Furthermore, biliary reflux in the
distal esophagus is a major concern as this has been shown to be
associated with increased incidence of metaplasia, dysplasia, and
finally esophageal adenocarcinoma (69). Nevertheless, data in
literature is widely lacking due to the relatively recent nature of
this procedure.
Preoperative endoscopic screening is of paramount
importance in order to rule out possible intraluminal
pathological alterations, including erosive esophagitis, hiatal
hernia, Barrett’s esophagus, malignant tumors, etc. This
evaluation is also necessary to properly assess patients who are
often asymptomatic for GERD, might have the aforementioned
conditions and might go unnoticed if a preoperative endoscopy
is not performed. A proper and complete examination, in fact,
can contribute to the correct patient selection and submission to
the best bariatric operation in that specific case, also contributing
to the reduction of postoperative complications.
The reported cases of esophagogastric cancers after BMS
are sporadic and insufficient, not allowing to reliably draw
a relationship between such types of malignancies and each
bariatric surgical procedure. Additionally, epidemiological
studies do not show a greater incidence of esophageal and
gastric cancers in post-bariatric subjects compared to the
general population (77). Nevertheless, higher-level evidence is
necessary to fully understand and eventually confirm or deny
any intercorrelation. Endoscopic surveillance after all types of
bariatric operations seems to be of paramount importance for
early detection of esophagogastric malignancies.
OBESITY SURGERY AND CANCER: WHAT
ARE THE UNANSWERED QUESTIONS?
Which Types of Cancers Benefit More
From BMS?
BMS appears to have protective effects on cancer development.
This anticarcinogenic action is multifactorial and includes
weight-dependent and independent mechanisms. There is a lack
of correlation between the entity of weight loss after BMS and
the decrease in cancer incidence. This is to confirm how BMS
exercises its effects not solely through weight loss, but is rather
likely to be mediated by various mechanisms (15).
The beneficial effects of BMS in terms of reduction of cancer
incidence and mortality has especially been shown in females,
specifically in the postmenopausal group (12, 13). Such positive
outcomes in females are likely to be associated with a substantial
decrease in estrogen production and bioavailability, translating
in a decline of hormone-sensitive breast and endometrial cancers
after BMS (34).
Why Does BMS Benefit More Women Than
Men?
It is certainly the remission of obesity that has been postulated
to be at the basis of cancer incidence reduction or prevention.
Mechanisms involved in obesity-related cancer genesis are
multiple and not completely elucidated. Some of these have
been suggested to occur through a depauperation of adipose
tissue, which causes in parallel a drop in estrogen circulating
levels, thereby altering the risk of hormone-sensitive cancers,
especially in postmenopausal women (12–15). Insulin resistance,
which is known to often co-exist with obesity, might also
have a role in augmented estrogen levels through interaction
in insulin signaling pathways, possibly causing exogenous
estrogen synthesis. Furthermore, several weight loss independent
modalities have been proposed to be involved in post-bariatric
surgery cancer risk decrease and include lowering of systemic
inflammation, changes in gastrointestinal hormones, alteration
of gastrointestinal anatomy which in turn produces alteration
of gut microbiota, fat, glucose, and bile metabolism. Hence,
hormonal levels are at the basis of the improved cancer risk
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especially in postmenopausal women (34, 35). However, several
mechanisms involved in this phenomenon are still waiting to
be clarified.
Does Only Cancer Risk Improve or Is Also
Prognosis Affected After BMS?
BMS not only affects cancer incidence but has also been
shown to profoundly influence cancer prognosis. This may
occur through several pathways that are in part correlated
to weight loss but also involve multiple mechanisms that go
beyond mere weight reduction and that seem to be associated to
metabolic modifications occurring after surgery. In fact, evidence
suggests that cancer prognosis is affected by insulin and IGF-
1 circulating levels, independently of cancer risk. Specifically,
a state of hyperinsulinemia is associated with worst cancer
prognosis and outcomes. In consideration of the ever-growing
prevalence of obesity and insulin resistance, an increasing
interest to the development of new experimental antineoplastic
drugs—targeting IGF-1 and/or insulin signaling pathways—are
being employed in clinical trials (14, 32).
Which Operation Should Be
Recommended for Each Specific Type of
Cancer?
No evidence is available at present regarding the beneficial effects
of different bariatric procedures on specific cancer types. In
consideration of this, the various surgical bariatric procedures
available should be advised by the bariatric surgeon based
on the preoperative work-up and available institutional and
international guidelines (78).
Does GERD Contraindicate Specific
Bariatric Procedures?
Currently, GERD, regardless of its severity, is not considered as
an absolute contraindication to any specific bariatric procedure.
However, several bariatric surgeons may oftentimes advice
the patient to undergo operations such as RYGB, which is
most effective in leading to GERD resolution, as opposed to
“refluxigenic” procedures such as SG (78, 79). In fact, SG
is controversially associated with an increase or worsening
of GERD and the appearance of hiatal hernia and erosive
esophagitis. The role of chronic GERD has been proven to
have a fundamental role in the genesis of gastroesophageal
malignancies. It is for this very reason that SG is often not
recommended in patients who have pre-existing GERD. Several
studies actually reported a significantly elevated number of
Barrett’s esophagus after SG. Barrett’s esophagus is indeed a
precancerous lesion and some authors have suggested that this
histological alteration might evolve to dysplasia even more
rapidly after this operation (66, 67). Esophageal adenocarcinoma
is in actual fact the most common malignancy emerging after
SG and postoperative endoscopic surveillance is fundamental for
early diagnosis in this group of patients (69, 70, 77).
CONCLUSIONS
Available data has shown that obesity is indeed associated with
an increased cancer risk and BMS is capable, through several
diverse pathways, to generate a significant reduction in overall
cancer prevalence and mortality. However, awareness should be
raised with regards to the possibility of increasing the incidence
of gastroesophageal cancers after BMS and the necessity of
postoperative endoscopic surveillance. Further understanding of
involved mechanisms in the development or reduction of such
neoplasms in this specific type of patients is required in order to
possibly formulate public health strategies in such setting.
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